Prophylactic agent or therapeutic agent for diabetes or obesity
A medicament having an excellent CaSR agonist action which enables the prevention or treatment of diabetes or obesity is provided by a composition comprising the compound represented by general formula (I) as defined, or a salt thereof.
1. A method for treating diabetes or obesity, comprising:
administering to a subject in need thereof, an effective amount of a glutamic acid compound represented by formula (I):
wherein R 1 , R 2 , R 3 , R 4 and R 5 each independently is selected from the group consisting of a hydrogen atom, a halogeno group, a hydroxyl group, a nitro group, an amino group, a C 1-6 alkyl group which may have a substituent(s), a C 1-6 alkoxy group which may have a substituent(s), a C 1-6 mono- or dialkylamino group which may have a substituent(s), a sulfo group, and a group:
provided that either one of R 1 , R 2 and R 3 is selected from the group consisting of a nitro group, a sulfo group and a group:
R 6 is a hydrogen atom, a hydroxyl group or a C 1-6 alkyl group which may have a substituent(s);
R 7 is a hydrogen atom or a C 1-6 alkyl group which may have a substituent(s);
X is a methylene group or an oxygen atom; and,
E is a hydroxyl group, a C 1-6 alkoxy group which may have a substituent(s), a mercapto group which may have a substituent(s), or a group:
wherein Z is selected from the group consisting of a divalent C 1-6 hydrocarbon group which may have a substituent(s), and E 2 is a hydrogen atom or a C 1-6 alkyl group;
or a pharmaceutically acceptable salt thereof.
2. A method according to claim 1 , wherein, in formula (I):
R 1 , R 2 , R 3 , R 4 and R 5 each independently is selected from the group consisting of a hydrogen atom, a halogeno group, a hydroxyl group, a nitro group, an amino group, a C 1-6 alkyl group which may have a substituent(s), a C 1-6 alkoxy group which may have a substituent(s), and a C 1-6 mono- or dialkylamino group which may have a substituent(s);
R 2 is selected from the group consisting of a nitro group, a sulfo group and a group:
R 6 and R 7 each independently is a hydrogen atom or a C 1-6 alkyl group which may have a substituent(s); and,
X is a methylene group or an oxygen atom.
3. A method according to claim 1 , wherein, in formula (I):
R 1 , R 3 , R 4 and R 5 each independently is selected from the group consisting of a hydrogen atom, a halogeno group, a hydroxyl group, a nitro group, an amino group, a C 1-3 alkyl group which may have a substituent(s), a C 1-3 alkoxy group which may have a substituent(s) and a C 1-3 mono- or dialkylamino group which may have a substituent(s);
R 2 is selected from the group consisting of a nitro group, a sulfo group, and a group:
and,
R 6 and R 7 each independently is a hydrogen atom or a methyl group.
4. A method according to claim 1 , wherein, in formula (I):
R 1 , R 3 , R 4 and R 5 each independently is selected from the group consisting of a hydrogen atom, a chloro or bromo group, a hydroxyl group, a nitro group, an amino group, a methyl group and a methoxy group;
R 2 is selected from the group consisting of a nitro group, a sulfo group and a group:
R 6 is a hydrogen atom or a methyl group;
R 7 is a hydrogen atom; and,
X is a methylene group.
5. A method according to claim 1 , wherein, in formula (I):
R 2 is a sulfo group, a carboxylic acid group or a phosphonic acid group.
6. A method according to claim 1 , wherein, in formula (I):
E is a hydroxyl group or a C 1-6 alkoxy group which may have a substituent(s).
7. A method according to claim 1 , wherein, in formula (I):
E is a C 1-6 alkoxy group or a group:
-0-Z-E 1 (IIa)
wherein, in formula (IIa):
Z is a divalent C 1-6 hydrocarbon group which may have a substituent(s), E 1 is a C 1-6 acyloxy group which may have a substituent(s), a C 1-6 alkoxycarbonyloxy group which may have a substituent(s), an amino group which may have a substituent(s), a carboxyl group, a C 1-6 alkoxycarbonyl group which may have a substituent(s), a halogen atom, an aryl group, a heteroaryl group, a C 1-6 alkoxy group which may have a substituent(s) or a carbamoyl group which may have a substituent(s), and Z and E 1 may be combined together to form a ring.
8. A method according to claim 1 , wherein the glutamic acid compound is administered in an amount of 0.000001% by weight to 99.9999% by weight based on a dry weight.
9. A method according to claim 1 , wherein the glutamic acid compound is administered in an amount of 0.00001% by weight to 99.999% by weight based on a dry weight.
10. A method according to claim 1 , wherein the glutamic acid compound is administered in an amount of 0.0001% by weight to 99.99% by weight based on a dry weight.